Plasma peroxiredoxin changes and inflammatory cytokines support the involvement of neuro-inflammation and oxidative stress in Autism Spectrum Disorder

• Published in: Journal of translational medicine Vol. 17; no. 1; pp. 332 - 12
• Main Authors: Abruzzo, P. M., Matté, A., Bolotta, A., Federti, E., Ghezzo, A., Guarnieri, T., Marini, M., Posar, A., Siciliano, A., De Franceschi, L., Visconti, P.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.10.2019; BioMed Central; BMC
• Subjects: (Neuro)inflammation; Antioxidants; Antioxidants (Nutrients); Autism; Autism Spectrum Disorder; Biochemistry; Bipolar disorder; Brain research; Children; Communication; Cytokines; Enzymes; Epigenetics; Gene expression; Genes; Health aspects; Inflammation; Interleukin 6; Mental disorders; Microglia; Mutation; Neurophysiology; Novels; Oxidative stress; Parents & parenting; Pathogenesis; Peroxiredoxin; Peroxiredoxins 1, 2, 3 and 5; Physiological aspects; Plasma; Plasma levels; Proteins; Red cells; Schizophrenia; Signal transduction; Therapeutic applications; United States; Oxidative stress; (Neuro)inflammation; Cytokines; Peroxiredoxins 1, 2, 3 and 5; AHR signaling pathway; Autism Spectrum Disorder; Red cells
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-019-2076-z

It has been established that children with Autism Spectrum Disorders (ASD) are affected by oxidative stress, the origin of which is still under investigation. In the present work, we evaluated inflammatory and pro-oxidant soluble signature in non-syndromic ASD and age-matched typically developing (TD) control children. We analyzed leukocyte gene expression of inflammatory cytokines and inflammation/oxidative-stress related molecules in 21 ASD and 20 TD children. Moreover, in another-comparable-group of non-syndromic ASD (N = 22) and TD (N = 21) children, we analyzed for the first time the protein expression of the four members of the antioxidant enzyme family of peroxiredoxins (Prx) in both erythrocyte membranes and in plasma. The gene expression of IL6 and of HSP70i, a stress protein, was increased in ASD children. Moreover, gene expression of many inflammatory cytokines and inflammation/oxidative stress-related proteins correlated with clinical features, and appeared to be linked by a complex network of inter-correlations involving the Aryl Hydrocarbon Receptor signaling pathway. In addition, when the study of inter-correlations within the expression pattern of these molecules was extended to include the healthy subjects, the intrinsic physiological relationships of the inflammatory/oxidative stress network emerged. Plasma levels of Prx2 and Prx5 were remarkably increased in ASD compared to healthy controls, while no significant differences were found in red cell Prx levels. Previous findings reported elevated inflammatory cytokines in the plasma of ASD children, without clearly pointing to the presence of neuro-inflammation. On the other hand, the finding of microglia activation in autoptic specimens was clearly suggesting the presence of neuro-inflammation in ASD. Given the role of peroxiredoxins in the protection of brain cells against oxidative stress, the whole of our results, using peripheral data collected in living patients, support the involvement of neuro-inflammation in ASD, and generate a rational for neuro-inflammation as a possible therapeutic target and for plasma Prx5 as a novel indicator of ASD severity.